Latest news with #357
TimesLIVE
16 hours ago
- Business
- TimesLIVE
How an opportunity in defence could make flying taxis a reality
Opportunities in defence, emergency healthcare and cargo could help make flying taxis a reality in the next few years after the sector recently received backing from US President Donald Trump's administration, executives in the industry said at the Paris Airshow. Trump this month told regulators to speed up certification to accelerate the development of electric vertical take-off and landing aircraft (eVTOLs), aiming to secure a US lead over Asia in the technology. The executive order gave fresh impetus to an industry that has struggled to win over critics and regulators. "We take a lot of spears, people are like 'batteries are too heavy'," Kyle Clark, founder and chief executive of Beta Technologies, said at the show. "But the reality is, if you put the airplanes in the right places, the benefits are real." Flying taxis - seen in predictions of the future for decades - need to shake off the idea that they are only for the rich to become viable at scale. Their manufacturers said emergency medical services, cargo and defence could help, where they offer a cheaper and quieter alternative to helicopters in areas from passenger and goods transport to rescue missions. BETA, Joby Aviation and Archer Aviation are in the US air force agility prime programme, which aims to develop technologies for autonomous cargo and hybrid-electric aircraft. Joby and Archer have previously signed military contracts worth $131m (R2,357,768,942) and up to $142m (R2,555,943,200), respectively. "We have two aircraft at Edwards air force base, and we are grateful for all the support an learning out of that," said Joby Aviation's founder and CEO JoeBen Bevirt. "We think there are incredible opportunities on the defence side." Clark, who flew Beta's conventional takeoff and landing aircraft in Paris, said the company had a clear position in defence: reliable aircraft that showed up to every mission.
GMA Network
4 days ago
- General
- GMA Network
No winners of major lotto jackpots on Monday, June 16, 2025
There were no winners of the Grand Lotto 6/55 and Megalotto 6/45 jackpot prizes drawn by the Philippine Charity Sweepstakes Office (PCSO) on June 16, 2025. The prize for Grand Lotto 6/55 is P47,492,275.40. The winning numbers are 36-32-28-14-49-45. No one also guessed the winning combination for Megalotto 6/45 which was 08-22-20-41-29-42. A bettor would have won the jackpot of P17,357,253.80. For more lotto results, check here. —RF, GMA Integrated News
New Straits Times
13-06-2025
- Business
- New Straits Times
Bursa Malaysia declines at midday as Washington's tariff plan weighs on sentiment
KUALA LUMPUR: Investor confidence remains under pressure amid a fragile global trade environment, as Washington announced its intention to send letters outlining unilateral tariffs to trading partners within two weeks, adding to existing economic uncertainties. At 12.30 pm, the key index retreated by 8.59 points or 0.56 per cent to 1,518.03 from Thursday's close of 1,526.62. The benchmark index had opened 4.15 points lower at 1,522.47 and moved between 1,515.10 and 1,522.70 during the session. In the broader market, losers overwhelmed gainers 798 to 177, with 357 counters unchanged, 1,089 untraded, and 17 suspended. Turnover stood at 1.94 billion units valued at RM1.07 billion. Hong Leong Investment Bank Bhd (HLIB) noted that broader market sentiment remains cautious amid lingering uncertainty over the pending US-Malaysia tariff agreement and the traditionally soft seasonality for June. "Investor confidence remains under pressure amid a fragile global trade environment, with the 90-day US reciprocal tariff reprieve on countries set to expire in early July (late August for China), and the approaching US debt ceiling deadline in August," it said in a research note today. HLIB also said the potential market impact from Malaysia's anticipated subsidy rationalisation in the second half of this year, coupled with the expanded sales and service tax (SST) rollout effective July 1, could dampen Malaysia's growth trajectory and cloud corporate earnings visibility in the near term. Among the heavyweights, Maybank lost seven sen to RM9.70, Public Bank was three sen easier at RM4.26, Tenaga Nasional rose two sen to RM14.28, CIMB declined four sen to RM6.85, IHH Healthcare shed two sen to RM6.88 and CelcomDigi eased three sen to RM3.76. In active trade, MYEG fell 1.5 sen to 95 sen, Velesto added half-a-sen to 18.5 sen, Tanco accumulated half-a-sen to 96 sen, while Sinaran Advance was flat at 3.5 sen. On the index board, the FBM Emas Index dropped 82.45 points to 11,362.47, the FBMT 100 Index erased 75.93 points to 11,138.34, and the FBM Emas Shariah Index tumbled 79.34 points to 11,318.17. The FBM 70 Index slipped 162.47 points to 16,340.19, and the FBM ACE Index declined 72.58 points to 4,452.11. Sector-wise, the Plantation Index firmed 35.38 points to 7,229.12 and the Energy Index garnered 13.83 points to 739.96, while the Industrial Products and Services Index shed 1.29 points to 150.9, and the Financial Services Index dwindled 120.30 points to 17,668.97.
Yahoo
20-05-2025
- Health
- Yahoo
PDAB weighs diabetes drug affordability, as Moore weighs bill to expand PDAB
Medication vials marked for calibration await counting at the Exchange Pharmacy at Joint Base Andrews, Md., July 27, 2023. (Photo by Staff Sgt. Jared Duhon/U.S. Air Force) A Maryland board tasked with bringing down prescription drug costs is working through a 'dossier' of a medication to treat type 2 diabetes — the first of many such reports to determine if there are ways for the state to save money on certain medications. The Prescription Drug Affordability Board unveiled a 92-page draft report Monday for Farxiga, a brand-name medication for dapagliflozin, to help board members determine if the drug is 'unaffordable' for Marylanders. It is the first of several dossiers analyzing the cost burdens of six popular prescription drugs in an effort to find avenues for the state to save on medications for those on the state's health plan. PDAB staff have been working on the Farxiga dossier since November, according to Andrew York, executive director for the board. He hopes that future dossiers will be easier to pull together now that staff have a format to work with. Six drugs were selected for 'cost review,' and address several conditions including Type 2 diabetes, heart disease, kidney disease, eczema, Crohn's disease and more. Dupixent Farxiga Jardiance Ozempic Skyrizi Trulicity 'I think staff now knows the time it takes to put these dossiers together,' York told the board during the virtual Monday meeting. 'That organizational process and cross referencing to make sure that everything is available to the board — that took a lot of time and effort. But now that that template's in place, I think we'll be moving forward pretty quickly.' Since the board's inception in 2019, it has been involved in a lengthy rule-making process to determine what drugs could be expensive for state employees and to establish methods to bring those costs down. In March 2024, PDAB board members officially selected six drugs to undergo the 'cost review' process, part of which includes an information gathering period to develop a dossier on the drugs. But the board has yet to bring down costs for any drugs on the state health plan. Meanwhile, Gov. Wes Moore (D) is expected to sign off on legislation Tuesday to expand the authority of the board to bring down costs for more Marylanders, not just those on the state plan. Critics in the legislature and the pharmaceutical industry cited the pace of the board's progress to argue unsuccessfully against expanding PDAB's authority, but House and Senate bills to do just that passed by comfortable margins this year. House Bill 424 and Senate Bill 357 would allow the board to establish what are called upper payment limits on the commercial market, to place a limit on how much the state is willing to pay for certain drugs. The board currently has that authority for state employees and others on the state health plan. The expanded authority would only go into effect a year after the board has successfully placed upper payment limits for two drugs on state health plans – meaning it will still be some time before the state can wield its new authority on the commercial market. But the dossier Monday sheds some light on different considerations that the board will use to determine if it will take action to reduce state spending on Farxiga — including overall state spending on the drug, prevalence of the diseases that the prescription drug treats, and costs of the disease to the health care system. In Maryland, about 10.5% of adults aged 18 years or older had been diagnosed with diabetes as of 2022 data, the report says. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX 'In Maryland, for calendar year 2021, total and per-patient medical costs attributable to diabetes were $6.506 billion and $11,909, respectively,' the report says, citing data from the American Diabetes Association. The dossier reports similar data for other conditions Farxiga is often prescribed to treat, such as heart failure and Chronic Kidney Disease. From 2022 through 2023, Maryland spent $1.4 million on the most common dosage of Farxiga (10 MG) for those on the state health plan – about 289 Marylanders, according to the dossier. The dossier reports that out-of-pocket costs for Farxiga can vary, depending on insurance coverage. The median cost for 10 milligrams of Farxiga cost $160 for those with commercial insurance in 2023, but those on the state health plan paid $60 for the same dose. Meanwhile, those on Medicare paid a median of $158.90, according to 2022 data. But portions of the report are redacted from the public due to confidentiality restrictions, and the dossier is not finalized yet. Following Monday's meeting, PDAB staff will make tweaks on the dossier to more clearly relay the information. The Farxiga dossier will then go up for a 15-day public comment period. Staff is working on a dossier for another drug that helps treat type 2 diabetes called Jardiance, which should also be available for public comment soon, according to York. The board still has to officially determine if Farxiga or Jardiance pose an 'affordability challenge' before board members can consider next steps to bring down costs, which could include setting upper payment limits. Savings for the state health plans still appear to be a ways off.
Hindustan Times
01-05-2025
- Entertainment
- Hindustan Times
Did Kim Kardashian's 9-year-old son hack her Instagram account? Here's why fans think so
Kim Kardashian's fans believe her 9-year-old son, Saint West, hacked into her Instagram account. The speculations arose following an unusual activity on her page on Wednesday. In a since-deleted post, a strange call to action was shared with her 357 million followers. The post featured a screenshot of what appeared to be Saint's YouTube channel, along with the message, 'Sub to Saint's channel,' Page Six reported. While there is no official word on what exactly happened, fans quickly rushed to the comment section, drawing speculations about Kim's eldest son using her account for promotion. 'Saint done hacked the IG for the promo lolol.. smart man,' one fan wrote. 'SAINT LEAVE YO MAMA PHONE,' a second added, while a third remarked, 'He's really going for it.' 'Saint sweetie please go get mommy's credit card and post the card digits,' yet another user quipped. According to the outlet, Saint may have started a new account after his previous channel under the username @TheGoatSaint was taken down last October after an incident involving Kamala Harris' meme. The 9-year-old's new YouTube account - @S4intsking appears to be a channel dedicated to Roblox videos. Last September, Kim announced the launch of Saint's YouTube channel on her Instagram Stories. 'I finally allowed Saint to have a You Tube Channel after signing an extensive contract. Please Subscribe!' she wrote at the time, per People. The SKIMS founder then followed up with a post featuring an informal contract signed by him. The contract titled, 'Contract between Saint West and Kim Kardashian,' read, 'I Saint West agree to follow my mom's rules in order to have a YouTube channel. I am not allowed to comment any personal family information. I am not allowed to film any personal information. I am not allowed to film while North is recording music,' per the outlet.
